Corvus Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
CRVS Corvus Pharmaceuticals Inc
GSBD Goldman Sachs BDC Inc
LTRN Lantern Pharma Inc
JGGC Jaguar Global Growth Corporation I
WHG Westwood Holdings Group Inc
BNOX Bionomics Ltd
PSO Pearson PLC
ERNA Eterna Therapeutics Inc
INDP Indaptus Therapeutics Inc
TSLX Sixth Street Specialty Lending Inc
Go

Health Care : Biotechnology | Small Cap Value
Company profile

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on development of immune modulator product candidates with the potential to treat solid cancers, T cell lymphomas, autoimmune, allergic and infectious diseases. Its lead product candidate is CPI-818, a selective, covalent inhibitor of ITK and is in a multi-center Phase 1/1b clinical trial in patients with various malignant T cell lymphomas. Its second product candidate, ciforadenant, is an oral, small molecule antagonist of the A2A receptor for adenosine designed to disable a tumor’s ability to subvert attack by the immune system by blocking the binding of immunosuppressive adenosine in the tumor microenvironment to the A2A receptor. Its third product candidate is mupadolimab, a humanized monoclonal antibody that is designed to react with a specific site on CD73. Its product candidate also includes CPI-182, an Anti-CXCR2 Antibody designed to block inflammation and myeloid suppression.

Closing Price
$1.41
Day's Change
-0.04 (-2.76%)
Bid
--
Ask
--
B/A Size
--
Day's High
1.47
Day's Low
1.40
Volume
(Light)
Volume:
113,943

10-day average volume:
183,018
113,943

Company Profile

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on development of immune modulator product candidates with the potential to treat solid cancers, T cell lymphomas, autoimmune, allergic and infectious diseases. Its lead product candidate is CPI-818, a selective, covalent inhibitor of ITK and is in a multi-center Phase 1/1b clinical trial in patients with various malignant T cell lymphomas. Its second product candidate, ciforadenant, is an oral, small molecule antagonist of the A2A receptor for adenosine designed to disable a tumor’s ability to subvert attack by the immune system by blocking the binding of immunosuppressive adenosine in the tumor microenvironment to the A2A receptor. Its third product candidate is mupadolimab, a humanized monoclonal antibody that is designed to react with a specific site on CD73. Its product candidate also includes CPI-182, an Anti-CXCR2 Antibody designed to block inflammation and myeloid suppression.

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
--
Price/Book (MRQ)
1.43x
Price/Cash Flow (TTM)
--
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

No historic growth available.

Short Interest

September 2023
Current Month
1.8M
Previous Month
1.4M
Percent of Float
4.16%
Days to Cover
3.2680 Days

Share Information

CRVS is in a share class of common stock
Float
43.8M
Shares Outstanding
49.0M
Institutions Holding Shares
53
40.27%

Financial Statements

Balance sheet

Values displayed are in thousands.

Income statement

Values displayed are in thousands.

Cash flow

Values displayed are in thousands.

Company Officers

  • Richard A. MillerChmn.
  • Leiv LeaCFO
  • William Benton JonesSr.VP
  • Ian T. Clark
  • Elisha P. Gould

Address

Insider Trading

During the most recent quarter, 10K shares were bought in insider trading.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2023. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.